Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GliAvAx: Avelumab and Axitinib for Recurrent Glioblastoma
NCT03291314Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, axitinib in glioblastoma (GBM), sponsored by UZ Brussel. Started May 2017; status: completed.
02
Drugs
avelumabaxitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03291314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291314.